- A Phase I study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)2021 | Second Faculty of Medicine
- Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial2022 | Second Faculty of Medicine
- A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy2018 | First Faculty of Medicine
- CD38: A target in relapsed/refractory acute lymphoblastic leukemia-Limitations in treatment and diagnostics2022 | Second Faculty of Medicine
- Recent advances in the management of pediatric acute lymphoblastic leukemia2016 | Second Faculty of Medicine